Match Document Document Title
7098377 IEX-1 knockout animals  
The invention provides methods and materials related to animals having a disrupted IEX-1 sequence. For example, the invention provides homozygous knockout (IEX-1 −/− ) animals and heterozygous...
7098375 Animal and cell models for type II diabetes and their use  
A transgenic diabetes type II model laboratory animal is disclosed which comprises β-cells expressing a dominant negative form (dnFGFR1c) of FGFR1c. Also disclosed is the use of the Ipf1/pdx1...
7098373 IL-18 transgenic animal  
Transgenic non-human mammals comprising a DNA with an exogenous IL-18 gene incorporated in it such that the exogenous IL-18 gene is skin-specifically expressed, or their offsprings. The transgenic...
7098372 Pharmaceutical compositions and methods of using secreted frizzled related protein  
Pharmaceutical compositions and methods of use in regulation of mammalian bone forming activities of SFRPs (secreted frizzled-related proteins) are disclosed. SFRPs are secreted receptors for Wnts...
7094948 Transgenic animals  
There is discloses a transgenic mouse over-expressing a potassium channel BEC1, which can be used as an effective tool for screening a substance for antidementia or a substance to improve learning...
7094947 Animals with high histamine productivity  
The invention of the present patent application provides, a histamine-hyperproductive animal, which is a non-human animal or progeny thereof obtained by ontogenesis of totipotent cell transfected...
7091396 Animals, cells and methods for production of detectably-labeled antibodies  
Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least...
7081561 Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof  
The invention provides gene-targeted non-human animals comprising a genetically modified apoE gene encodes a recombinant apoE polypeptide displaying domain interaction. The invention further...
7081562 Model animal with favorite onset or rheumatoid arthritis  
The present invention provides a model animal with favorite onset of rheumatoid arthritis wherein the severity of arthritis reaches the maximum level and its onset ratio is a hundred percent, and a...
7078585 Bacterial cell component-unresponsive model mouse  
A knockout mouse which is unresponsive to peptidoglycan, a lipoprotein/lipopeptide and the like, and is useful for elucidating the contribution of individual members of the TLR family to a...
7067714 N-calcium channel knockout animal  
A non-human animal in which a gene coding for the N-type calcium channel is disrupted to lack functional N-type calcium channel, and a method for screening for a substance having a pharmacological...
7067712 Caspase 1 gene transfer animal  
A transgenic rodent or its offspring which carries DNA having an exogenous caspase 1 gene integrated thereinto in such a manner as to express the gene specifically to the skin. The transgenic...
7067713 C1 Inhibitor produced in the milk of transgenic non-human mammals  
The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring...
7064244 Transgenic mammals having human Ig loci including plural VH and VK regions and antibodies produced therefrom  
The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig...
7060871 Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function  
The present invention deals with gene therapy for treating chronic heart failure and other cardiac disease states which are accompanied by a reduced number or functioning of myocardial...
7060869 Fluorescent protein sensors for detection of analytes  
Fluorescent indicators including a binding protein moiety, a donor fluorescent protein moiety, and an acceptor fluorescent protein moiety are described. The binding protein moiety has an...
7060870 Transgenic mice over-expressing ABAD and mutant APP in brain as model of Alzheimer's disease and uses thereof  
The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter operatively linked to a DNA sequence which...
7057086 Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors  
A method of testing a candidate composition for PAI-1 inhibition activity is disclosed. The method includes the steps of obtaining a transgenic non-human warm blooded vertebrate animal having...
7049426 Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions  
The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy...
7045677 Fusion proteins incorporating lysozyme  
A process for the production of a peptide is disclosed, the process comprising expressing in the milk of a transgenic, non-human, placental mammal a fusion protein which comprises the peptide to be...
7045678 Transgenic mouse for screening therapeutic agents for brain tumors  
A transgenic, non-human mammal useful for assessing the effect of candidate chemotherapeutic drugs on the growth of brain tumors in vivo is provided. Incorporated into the genome of the transgenic...
7045675 Genes for Niemann-Pick type C disease  
A gene for type C Niemann-Pick disease (NP-C) is disclosed, along with the amino acid sequence of the encoded peptide. Applications which are made possible by the present invention include...
7041870 Transgenic transchromosomal rodents for making human antibodies  
The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
7041871 Transgenic non-human animals capable of producing heterologous antibodies  
The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial...
7038105 Transgenic mouse EDG2 knockout model  
The present invention provides a transgenic non-human animal and method for using the same in evaluating a therapeutic agent for use in the treatment of Schizophrenia. More specifically, the...
7034200 Non-human transgenic animals expressing platelet-derived growth factor C (PDGF-C) and uses thereof  
Non-human transgenic animals overexpressing PDGF-C and cells thereof have been created. The transgenic animals contain a nucleotide sequence that encodes for platelet derived growth factor C...
7030289 Stabilization of milk from transgenic animals  
The present invention relates to the stabilization of milk from transgenic animals. In particular, the invention relates to the protection of proteins (e.g. fibrinogen) expressed in milk from...
7030291 CYT28 serpentine receptor disruptions, compositions and methods relating thereto  
The present invention relates to compositions and methods relating to the characterization and function of CYT28. Specifically, the present invention provides transgenic animals comprising...
7022892 Non-human genetically modified mammal lacking the alpha-fetoprotein  
The present invention is related to a non-human genetically modified mammal comprising a mutation, a partial or total deletion of the genetic sequence encoding the wild type mammal alpha-fetoprotein.
7022893 Knockin gene-mutated mouse comprising a mutant presenilin-1 gene  
A gene-mutated animal such as a mouse which comprises a mutant prsenilin-1 gene comprising a DNA having a sequence encoding a mutant presenilin-1 protein in which an amino acid is substituted with...
7019194 SCCE modified transgenic mammals and their use as models of human disease  
Genetic evidence that an imbalance in the activity of serine proteases can cause severe skin disease has recently been presented. The serine protease SCCE is preferentially expressed in cornifying...
6998514 Murine expression of a human IgA lambda locus  
In humans, approximately 60% of expressed immunoglobulin light chains are of the Kappa type and 40% of the Lambda type. In mice, there is almost no expression from the Lambda locus and over 95% of...
6995298 Transgenic mammals expressing mutant GP IIIa  
The present invention relates to mammals into which foreign DNA has been introduced or in which various modifications or substitutions have been made to an integrin β subunit, thereby generating...
6992234 FcRn-based therapeutics for the treatment of auto-immune disorders  
Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous FcRn disruption prevents the expression of a functional FcRn...
6987211 Transgenic non-human mammals producing a cholinesterase in their milk  
The present invention relates to novel alternative forms of human acetylcholinesterase (AChE) and nucleotide sequences encoding the same. The genes encoding the novel forms of human AChE have been...
6984772 Transgenic non-human mammals producing fibrinogen in their milk  
A transgenic, non-human mammalian animal is capable of expressing a heterologous gene for human or other recombinant physiologically functional fibrinogen holoprotein or individual subunit chain...
6984771 Mice heterozygous for WFS1 gene as mouse models for depression  
The present invention describes a recombinant rodent model for depression. More particularly, the rodent comprises cells expressing mutations in the WFS1 gene. The rodent is preferably a mouse...
6984773 Transgenic mice expressing a human SXR receptor polypeptide  
A novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), a broad-specificity sensing receptor that is a novel branch of the nuclear receptor superfamily, has been discovered. SXR...
6982362 α-tocopherol transport protein knockout animal  
The present invention provides a knockout animal artificially modified to inhibit α-TTP gene expression. This animal is useful as a tool for understanding mechanisms for the development of...
6982361 Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal  
Methods and compositions for use in treating anxiety are provided. In the subject methods, an effective amount of an agent having ApoE3 activity is administered to a host suffering from an anxiety,...
6977157 Clock gene promoter  
The present invention discloses a Period2 gene promoter, a construct containing the promoter and a reporter gene, a cell containing the construct, a transgenic animal harboring the construct, and a...
6962688 Methods for modulation of cholesterol transport  
Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen...
6962975 Prion protein standard and method of making the same  
The invention provides prion protein standards for use as reference materials for prion detection. The standard may be species specific, i.e. the standard is comprised of a preparation for...
6958433 Transgenic mice overexpressing aspartyl protease 2 (ASP2)  
The present invention provides a recombinant DNA construct comprising a coding sequence encoding human ASP2 and a brain-specific calcium calmodulin kinase promoter sequence which is operably linked...
6956145 Mice models of human prostate cancer progression  
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
6953874 Transgenic animals having a modified glycoprotein V gene  
The present invention relates to nonhuman transgenic animals in which the GP V gene has been modified. The invention is also useful for identifying agents that modulate the biological functions of...
6949337 Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle  
The present invention provides methods of identifying anti-HIV compound by contacting human Vpr Interacting Protein (hVIP), or a fragment thereof known to interact with Vpr, with Vpr, or a fragment...
6949691 Human albumin animal models for drug evaluation, toxicology and immunogenicity studies  
An animal model is provided which is genetically engineered to express human serum albumin, and such animals may be advantageously used in assessing drugs, vaccines or other therapeutic compounds...
6943277 Transgenic mice containing stefin homolog protease inhibitor gene disruptions  
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
6933422 Nav2 channel gene-deficient mice  
An object of the present invention is to provide a null mutant non-human animal showing salt intake behavior similar to that of wild-type animals under water-sufficient conditions and showing much...